Detail akcie Infinity online

Business Summary: Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.
Financial Summary: BRIEF: For the six months ended 30 June 2023, Infinity Pharmaceuticals Inc. revenues decreased 2% to $1.3M. Net loss decreased 14% to $21M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Other Research and development decrease of 33% to $11.6M (expense), Investment and other income increase from $93K to $716K (income).